X4 Pharmaceuticals (XFOR) Current Assets (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Current Assets for 10 consecutive years, with $218.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 200.04% year-over-year to $218.9 million; the trailing twelve-month figure through Jun 2026 stood at $218.9 million (up 200.04% YoY), and the FY2025 full-year result was $261.6 million, up 133.19% from the prior year.
• Current Assets slipped to $218.9 million in Q2 2026 per XFOR's latest filing, from $242.0 million in the prior quarter.
• Across five years, Current Assets topped out at $261.6 million in Q4 2025 and bottomed at $52.6 million in Q2 2022.
• Historically, Current Assets has averaged $133.1 million across 5 years, with a median of $125.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Current Assets sank 58.42% in 2025, then surged 200.04% in 2026.
• Over 5 years, Current Assets stood at $128.7 million in 2022, then retreated by 5.13% to $122.1 million in 2023, then fell by 8.11% to $112.2 million in 2024, then surged by 133.19% to $261.6 million in 2025, then retreated by 16.33% to $218.9 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $218.9 million, $242.0 million, and $261.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.